Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

KiOmed Pharma

Request full access

Animal-free chitosan medical devices for degenerative diseases

Liège, BelgiumFounded 2012Biotech & Life Sciences

About KiOmed Pharma

KiOmed Pharma is a Belgian biotechnology company that develops, manufactures, and distributes medical devices based on its proprietary animal-free chitosan biopolymer, KiOmedine®. Founded in 2012 by François Blondel and spun out from KitoZyme, the company targets high-impact pathologies such as osteoarthritis, skin aging, and eye disorders. Blondel, who serves as Executive Chairman, has a background in law and economics and experience in managing technology and healthcare companies. Houtaï Choumane has been the CEO since the company's inception in 2014 and has nearly two decades of experience in the biotech industry, including a previous role as CEO of Artialis S.A., which specialized in biomarkers for musculoskeletal disorders.

The company's core technology, KiOmedine®, is a medical-grade carboxymethyl chitosan (CM-Chitosan) derived from mushrooms, offering an alternative to traditional animal-based chitosan sourced from shellfish. This technology is designed to have high purity, biocompatibility, and provides benefits such as tissue lubrication, protection against oxidative stress, and collagen synthesis stimulation. KiOmed's business model focuses on developing and commercializing a pipeline of injectable medical devices for rheumatology, aesthetic medicine, and ophthalmology. The company generates revenue through the sale of its products and strategic partnerships for global commercialization, including royalty and milestone payments.

One of KiOmed Pharma's key products is KioMedinevsone, a single-injection treatment for knee osteoarthritis symptoms that launched in several European and Middle Eastern markets in 2022. The company has established strategic partnerships to expand its market reach, including collaborations with Hansoh Pharmaceutical for distribution in China and Sinclair for the aesthetic sector. In March 2025, KiOmed Pharma secured €18 million in funding to support the international growth of KiOmedine® and accelerate development in its other focus areas. The company has also partnered with digital therapeutics firm moveUP to create a mobile health application for personalized osteoarthritis treatment.

Source: Dealroom company data

At a glance

Status
Operational
Employees
46
Open positions
None listed
Dealroom signal
83.2/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Spinout, Sustainable Development Goals, Biotech and Pharma, Climate Tech, Horizon Europe, DT and LS, science-based
Technology
Deep Tech
Business model
Manufacturing
Client focus
B2B

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
DEBT✓Debt Mar 2025 $8.8M — Noshaq · European Union · Public Service of Wallonia · Kitozyme ↗
LATE VC✓Equity / VC Mar 2025 $11M $44M Public Service of Wallonia · Noshaq · European Union · Kitozyme ↗
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

KiOmed Pharma website traffic

Latest recorded traffic for KiOmed Pharma is 460 monthly website visits, up 9.5% over the last three months. KiOmed Pharma's team grew 130% over the past year.

Latest monthly visits460 3-month web change+9.5% 1-year team growth+130%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

CompanyHeadquartersStatusEmployeesTotal fundingValuation
Sea4UsSea4Us is a biopharmaceutical startup specializing in discovering and developing new drugs, leveraging expertise in ion channels and marine biology Vila do Bispo, Portugal Operational 26 $6.2M $23M
HolloidProvides real-time multi-dimensional data on colloids, based on 3D imaging, with the throughput of cytometry Vienna, Austria Operational
AquaporinDeveloping advanced biotechnologies to purify water and desalinate seawater Kongens Lyngby, Denmark Operational
PepticomAn Artificial Intelligence (AI) company for the discovery of novel molecules in the Pharmaceutical and Agricultural markets Jerusalem, Israel Operational
Molecular AttractionEco-friendly bio-attractants for vector-borne disease control Solna kommun, Sweden Operational
ALGAIAIs a company developing, producing and commercializing Natural Extracts, mostly made out of seaweed Lannilis, France Acquired
PROSION TherapeuticsPROSION Therapeutics is a drug development company with a proprietary platform that addresses highly unmet medical needs by unlocking undruggables Cologne, Germany Operational
NeuroKaireGenetika+ is developing a tailored medical diagnostic instrument to help doctors cure depression. Genetika+ predicts the best pharmacological treatment for each patient, allowing faster treatment Kearny, United States Operational
Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

KiOmed Pharma in the Liège ecosystem

Live from Dealroom

The KiOmed Pharma office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A2 investors entered at this stage

  • Public Service of Wallonia
  • Noshaq

Series B and later2 investors entered at this stage

  • European Union
  • Kitozyme

Other known investors2 additional known investors

  • University of Liège
  • WE Venture
Team profiled 3 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

See KiOmed Pharma’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.